Please login to the form below

Not currently logged in
Email:
Password:

Novo Nordisk appoints new general manager

Pinder Sahota also becomes the corporate vice president, UK

Pinder SahotaDanish pharma group Novo Nordisk has appointed a new general manager and corporate vice president, UK, in the form of Pinder Sahota.

Sahota, who brings experience from business, commercial and leadership roles to Novo, was most recently responsible for creating commercial and market development strategies across Europe as senior vice president of market and commercial development for Europe at Smith & Nephew.

He said: “I am delighted to join Novo Nordisk in the role of general manager in the UK.

“The vision, values and passion that is immediately evident within the company makes Novo Nordisk and exciting organisation to be a part of.

“I look forward to working closely with my new colleagues with the aim of accelerating our business growth while positively impacting the healthcare ecosystem within which we operate, as well as supporting a positive internal culture and the development of strong talent at every level of our UK organisation.”

Sahota started his pharmaceutical career in sales and marketing with companies which formed Sanofi Aventis, before moving to SmithKline Beecham - now GlaxoSmithKline - where he held a number of commercial leadership roles including vice president of commercial operations of diabetes and cardiovascular.

In 2009 Sahota moved to AstraZeneca to assume the role of vice president for primary care in the UK, a position he held up until moving to the role of managing director for the UK and Ireland for Smith & Nephew in 2013.

Matt Regan, senior vice president, region Europe for Novo Nordisk, said: “Pinder’s extensive experience and knowledge will be a real strength as Novo Nordisk navigates the evolving UK landscape.”

12th April 2018

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics